The adeno-associated viral vector market is anticipated to grow at a CAGR of more than 10% by 2035

Berry_cristan24 Nov, 2022Health

Given their low immunogenicity, diversified targets and ability to offer higher biosafety, the adeno-associated viral vectors are actively being evaluated for the development of various therapies for the treatment of chronic diseases and infections. Owing to their unique biology, simple structure and lack of disease correlation, the adeno-associated viral vectors have garnered significant interest within the medical community.